Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae:: Report from the antimicrobial resistance rate epidemiology study team

被引:49
作者
Jones, RN
Rubino, CM
Bhavnani, SM
Ambrose, PG [1 ]
机构
[1] Cognigen Corp, Div Infect Dis, Buffalo, NY 14221 USA
[2] JONES Grp, JMI Labs, N Liberty, IA USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
[4] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
[5] Univ Pacific, Sch Hlth Sci, Stockton, CA 95211 USA
关键词
D O I
10.1128/AAC.47.1.292-296.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of fluoroquinolones for the treatment of community-acquired respiratory tract infection is increasing. Since for Streptococcus pneumoniae a ratio of the 24-h area under the concentration-time curve (AUC(24)) for the agent to the MIC (AUC(24)/MIC) greater than 30 for the fraction of unbound drug (Q is the major pharmacokinetic-pharmacodynamic (PK-PD) parameter correlating with bacterial eradication by fluoroquinolones in nonclinical models of infection and in infected patients, the Antimicrobial Resistance Rate Epidemiology Study Team systematically compared the in vitro susceptibility patterns and estimated the probability of attainment of the PK-PD target ratios for gatifloxacin and levofloxacin against pneumococci worldwide. Monte Carlo simulation was used to estimate the probability that gatifloxacin or levofloxacin would achieve an f(u) AUC(24)/MIC ratio of 30 or greater. A total of 10,978 S. pneumoniae isolates collected from 1997 to 2000, each indexed by site of infection and geographic region (North America, Latin America, Europe, and Asia-Pacific), were used to estimate the probability mass functions of the microbiological activities for each region considered in the analysis. f(u) AUC24 probability distribution functions were estimated by using data that were part of each product's submission accepted by the Food and Drug Administration. A 10,000-patient simulation was performed for each drug-organism-region combination. The percentages of strains susceptible to each drug by region were as follows: for gatifloxacin, North America, 99.6%; Latin America, 99.8%; Europe, 99.9%; and Asia-Pacific, 99.2%; for levofloxacin, North America, 99.6%; Latin America, 99.8%; Europe, 99.8%; and Asia-Pacific, 99.1%. The MIC at which 50% of isolates are inhibited (MIC50) and the MIC90 of each drug by region were as follows: for gatifloxacin, North America, 0.25 and 0.5 mg/liter, respectively; Latin America, 0.25 and 0.5 mg/liter, respectively; Europe, 0.25 and 0.5 mg/liter, respectively; and Asia-Pacific, 0.25 and 0.5 mg/liter, respectively; for levofloxacin, North America, I and 2 mg/liter, respectively; Latin America, I and 2 mg/liter, respectively; Europe, 1 and I mg/liter, respectively; and Asia-Pacific, I and I mg/liter, respectively. The probabilities of attaining an f(u) AUC(24)/MIC ratio greater than 30 for each drug by region were as follows: for gatifloxacin, North America, 97.6%; Latin America, 98.3%; Europe, 99.1%; and Asia-Pacific, 98.8%; for levofloxacin, North America, 78.9%; Latin America, 84.1%; Europe, 87.1%; and Asia-Pacific, 86.5%. These results for a very large collection of recent clinical strains demonstrate that, globally, gatifloxacin is two- to fourfold more active than levofloxacin against S. pneumoniae and that gatifloxacin has an overall 14.3% higher probability of achieving clinically important PK-PD target ratios than levofloxacin.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 19 条
[1]   Antimicrobial pharmacodynamics [J].
Ambrose, PG ;
Owens, RC ;
Grasela, D .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (06) :1431-+
[2]   The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs:: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae [J].
Ambrose, PG ;
Grasela, DM .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :151-157
[3]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[4]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[5]  
Craig W. A., 2001, ANTIMICROBIAL PHARMA, P1
[6]   In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae [J].
Davies, TA ;
Pankuch, GA ;
Dewasse, BE ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1177-1182
[7]   Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint [J].
Drusano, GL ;
Preston, SL ;
Hardalo, C ;
Hare, R ;
Banfield, C ;
Andes, D ;
Vesga, O ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :13-22
[8]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490
[9]  
Dudley M. N., 2001, ANTIMICROBIAL PHARMA, P67
[10]   Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints:: ready for prime time [J].
Dudley, MN ;
Ambrose, PG .
CURRENT OPINION IN MICROBIOLOGY, 2000, 3 (05) :515-521